Recognizing excess visceral abdominal fat

Recognizing Excess Visceral Abdominal Fat

Central adiposity in HIV is marked by excess visceral abdominal fat

People with HIV (PWHIV) have an increased risk in developing excess visceral abdominal fat.¹

Excess visceral abdominal fat is the abnormal accumulation of visceral fat in the abdominal cavity and is present around internal organs.²

Understanding central adiposity in HIV

The pathogenesis of excess visceral abdominal fat in PWHIV appears to be multifactorial, including contributions from:²

Antiretroviral therapy (ART)
HIV infection itself
Growth hormone (GH) deficiency³

Identify excess visceral abdominal fat with 3 simple steps²

1

Palpate the midsection for firmness or rigidity

2

Measure waist and hip circumferences

3

Calculate
waist‑to‑hip ratio^†

Calculate your patients’ waist‑to‑hip ratio

Ensure both circumferences are entered with the same unit.

Indicators for excess visceral abdominal fat:^2†‡

MEN

Waist circumference
≥37.4 in (95 cm)

Waist-to-hip ratio ≥0.94

WOMEN

Waist circumference
≥37 in (94 cm)

Waist-to-hip ratio ≥0.88

BMI and WC are independently associated with predicting excess visceral abdominal fat.^4,5

BMI = body mass index; WC = waist circumference.
† Waist‑to‑hip ratio = waist circumference/hip circumference.
‡ Reference values are based on inclusion criteria in clinical trials.

References:

Moyle G, Moutschen M, Martínez E, et al. Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection. AIDS Rev. 2010;12(1):3-14.
Lake JE, et al. Practical review of recognition and management of obesity and lipohypertrophy in human immunodeficiency virus infection. Clin Infect Dis. 2017;64(10):1422-1429.
Rietschel, P, Hadigan C, Corcoran C, et al. Assessment of growth hormone dynamics in human immunodeficiency virus‑related lipodystrophy. J Clin Endocrinol Metabolism. 2001;86;504-10.
Janssen I, Heymsfield SB, Allison DB, Kotler DP, Ross R. Body mass index and waist circumference independently contribute to the prediction of nonabdominal, abdominal subcutaneous, and visceral fat. Am J Clin Nutr. 2002;75(4):683-688.
Joy T, Keogh HM, Allison DB, Hadigan C, et al. Relationship of Body Composition to BMI in HIV‑Infected Patients with Metabolic Abnormalities. J Acquir Immune Defic Syndr. 2008;47(2):174-84.

IMPORTANT SAFETY INFORMATION (Please see below for full limitations of use and additional important safety information)

Indication

EGRIFTA SV^® is indicated for the reduction of excess abdominal fat in people with HIV and lipodystrophy.

Limitations of Use:

The impact and safety of EGRIFTA SV^® on cardiovascular health have not been studied.
EGRIFTA SV^® is not indicated for weight loss management.
It is not known whether taking EGRIFTA SV^® helps improve compliance with anti‑retroviral medications.

Contraindications:

Do not use EGRIFTA SV^® if patient:

Has a pituitary gland tumor, has had pituitary gland surgery, has other problems related to their pituitary gland, or has had radiation treatment to their head or a head injury.
Has active cancer.
Is allergic to tesamorelin or any of the ingredients in EGRIFTA SV^®.
Is pregnant or planning to become pregnant.

Warnings and Precautions

Increased risk of neoplasms: Preexisting malignancy should be inactive, and its treatment complete prior to starting EGRIFTA SV^®. EGRIFTA SV^® should be discontinued if the patient has evidence of recurrent malignancy.

Elevated IGF‑1: Monitor regularly IGF‑1 levels in all patients during EGRIFTA SV^® therapy. Consider discontinuing in patients with persistent elevations (e.g., >3 SDS).

Fluid retention: May include edema, arthralgia, and carpal tunnel syndrome.

Glucose intolerance or diabetes mellitus: May develop with EGRIFTA SV^® use. Evaluate glucose status prior to and during therapy with EGRIFTA SV^®.

Hypersensitivity reactions: Advise patients to seek immediate medical attention and discontinue treatment if suspected.

Injection site reactions: Advise patients to rotate injection sites to different areas of the abdomen to decrease injection site reactions.

Increased mortality in patients with acute critical illness: Consider discontinuation in critically ill patients.

Drug Interactions

EGRIFTA SV^® had no significant impact on the pharmacokinetic profiles of simvastatin in healthy subjects.

Monitor patients for potential interactions when administering EGRIFTA SV^® in combination with other drugs known to be metabolized by CYP450 liver enzyme.

Patients on glucocorticoids may require dosage adjustment upon initiation of EGRIFTA SV^®.

Use in Specific Populations

Lactation: Mothers should not breastfeed if they receive EGRIFTA SV^®.

Pediatric Use: Safety and effectiveness in pediatric patients have not been established.

Geriatric Use: There is no information on the use of EGRIFTA SV^® in patients greater than 65 years of age.

Adverse Reactions

The most commonly reported adverse reactions include injection site reactions, arthralgia, pain in extremity, myalgia, and peripheral edema.

For more information about EGRIFTA SV^®, contact

toll‑free at 1‑833‑23THERA (1‑833‑238-4372).To report suspected adverse reactions, contact

at 1‑833‑23THERA (1‑833‑238-4372) or FDA at 1‑800‑FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for EGRIFTA SV^®.